Search PubMed⌕ Search

Biomedical subjects

C J Bulpitt

Publications and source records attributed to C J Bulpitt.

At least 91 records · Page 5Linked to original sources
PubMed1994

The effect of low dose lofepramine in depressed elderly patients in general medical wards.

A double-blind randomised controlled trial of the effect of low dose lofepramine (70 mg once daily) against placebo was carried out on depressed elderly inpatients on general medical wards for the elderly, comparing measures of depression and side-effects between the randomised groups. Patients were identified for the study using the Geriatric Depression Scale (GDS) and the Brief Assessment Schedule Depression Cards (BASDEC). Sixty-three subjects were randomised: 46 patients completed the entire trial of 28 days treatment. BASDEC and GDS were administered on day 8 post-admission, and depressed patients were randomised double-blind to either low dose lofepramine (70 mg daily) (n = 23) or placebo (n = 23). Assessment of changes in depressive states were made using the Montgomery Asberg Depression Rating Scale (MADRS) on days 8, 18 and 36 post-admission. Both groups improved by a similar amount during the trial. Lofepramine tended to be more effective than placebo in those patients who were more depressed (GDS > or = 18). On the other hand, subjects who were less depressed (i.e. GDS < 18) improved more on placebo than lofepramine. Low dose lofepramine may prove useful in moderately or severely depressed patients treated for only 4 weeks. However, low dose lofepramine is not indicated for mild (GDS 15-18) depression.

Administration, Oral↗
PubMed1994

Optimal blood pressure control in treated hypertensive patients. Report from the Department of Health Hypertension Care Computing Project (DHCCP).

BACKGROUND: We wished to determine the range of treated systolic (SBP) and diastolic blood pressure (DBP) associated with the best survival in hypertensive patients. METHODS AND RESULTS: We conducted a cohort study of patients enrolled in the DoH Hypertension Care Computer Project. Five specialist hypertension clinics (95% of patients) and general practitioners (5%) followed 6214 patients (3070 men and 3144 women) with an average age of 52 years for a mean of 107 months. Total, cardiovascular, ischemic heart disease, (IHD) and stroke mortality were the outcome measures. Age-adjusted relative hazard rates were calculated giving the effect on mortality of systolic or diastolic pressure being higher by 1 mm Hg. In men the optimal level of SBP for all four measures of mortality was the lowest pressure range observed, 92 to 133 mm Hg (median 127). For women the treated SBP range of 96 to 148 mm Hg (median 137) was associated with a low total mortality and also with low to moderate rates for IHD and stroke mortality. Relative hazard rates (P < .001) for IHD mortality were 1.010 for men and 1.013 for women and for stroke mortality were 1.018 and 1.021, respectively. The results were similar in men under and over the age of 60. SBP and DBP tended to be more important in younger than older women. For treated DBP in men, a pressure of 55 to 94 mm Hg (median 87) was associated with a low total mortality. The lowest stroke mortality in men was observed for a DBP range of 55 to 83 mm Hg (median 80) but with a tendency for an increase in IHD mortality. For women DBP < 95 mm Hg (range 55 to 94, median 87) also was associated with a low total mortality. IHD mortality in women was not closely related to treated DBP, relative hazard rate = 1.003, [95% confidence index (CI); 0.990,1.017] but the relative hazard rate for men was 1.011, (95% CI; 1.000, 1.022). The relative hazard rates for treated DBP and stroke were high at 1.035 and 1.028 for men and women, respectively (P < .001). IHD mortality increased in the one third of patients with the greatest fall in DBP on treatment, provided they were not initially in the one-third group with highest untreated DBP. CONCLUSIONS: The best overall survival was associated with a treated SBP of < 134 mm Hg in men and < 149 mm Hg in women and a treated DBP of < 95 mm Hg.

Adult↗
PubMed1994

The Hypertension in the Very Elderly Trial (HYVET). Rationale, methodology and comparison with previous trials.

The Hypertension in the Very Elderly Trial (HYVET) is a multicentre, open, randomised, controlled trial. The aim of this trial is to investigate the effect of active treatment on stroke incidence in hypertensive patients over the age of 80 years. Secondary end-points include total cardiovascular mortality and morbidity. Entry criteria include a sustained sitting systolic blood pressure of 160 to 219mm Hg plus a sustained sitting diastolic pressure of 95 to 109mm Hg. Also required is a standing systolic blood pressure of at least 140mm Hg. Patients must give their informed consent, and be free of congestive heart failure requiring treatment, gout, renal failure or a recent cerebral haemorrhage. Patients are to be randomised to 3 groups-(i) no treatment; (ii) treatment with a diuretic [bendroflumethiazide (bendrofluazide)]; or (iii) treatment with an angiotensin converting enzyme (ACE) inhibitor (lisinopril). Starting dosage for bendroflumethiazide and lisinopril is 2.5 mg/day. In order to achieve goal sitting systolic and diastolic blood pressures (< 150/80 mm Hg), a doubling of the dosage is allowed. Furthermore, slow release diltiazem (120 mg/day increasing to 240 mg/day if required) may be added to the medication of the actively treated groups. These drugs have been chosen as inexpensive and appropriate representatives of their therapeutic classes. 700 patients in each group (a total of 2100) will be sufficient to detect a 40% difference in cerebrovascular events between no treatment and active treatment (alpha = 0.01, 1-beta = 0.90). These numbers will also detect a difference in total mortality of 25% and in cardiovascular mortality of 35%. The pilot phase of the trial has been started with support from the British Heart Foundation. Centres which are interested in taking part should contact C.J. Bulpitt or any of the other authors.

Aged↗
PubMed1994

Prognostic significance of blood pressure in the very old. Implications for the treatment decision.

A positive relationship between blood pressure and mortality at the age of 60 to 69 years becomes a negative relationship in men over the age of 75 years and in women over the age of 85 years, with hypertensive individuals living longer. This negative relationship in very old people probably reflects cardiac, respiratory and neoplastic disease in those with low blood pressure, and good myocardial function in those with high blood pressure. Therefore, in very elderly hypertensive people we cannot conclude that a reduction in blood pressure will not be beneficial, e.g. in reducing stroke events. However, the results of clinical trials of antihypertensive treatment in the elderly provide inadequate evidence to assess the benefit of treating hypertensive individuals over the age of 80 years. Randomly allocated controlled trials are required in this age group. The antihypertensive treatments that may be most suitable for the very elderly are diuretics with a beta-adrenergic blocking drug added if necessary. Angiotensin converting enzyme (ACE) inhibitors and calcium channel blockers have not, as yet, a proven role in the treatment of hypertension in the very old.

Aged↗
PubMed1994

Quality-of-life instruments in hypertension.

This review considers the choice of dimensions to be assessed and the practical problems of measuring quality of life in hypertensive patients. The dimensions of symptomatic well-being, psychological well-being, sleep, sexual function and cognitive function should be assessed. Symptomatic well-being may be measured by many different instruments, and that devised by the authors has been used extensively. The results in different trials may therefore be examined for consistency and sensitivity. Psychological well-being has been assessed by the Psychological General Well-Being Index, the Symptom Rating Test and the Profile of Mood States. The response of these instruments is discussed. The assessment of sleep, sexual function and cognitive function is also described. It is recommended that quality-of-life instruments to be employed in trials of antihypertensive drugs are known to be sensitive to the effects of such drugs.

Attitude to Health↗
PubMed1994

Psycho-emotional stress and salt intake may interact to raise blood pressure.

AIM: This study examined whether work-related aspects of stress, alone or in association with a high salt intake, are associated with a raised blood pressure. METHODS: A total of 384 male civil servants (35-51 years) collected a 24h urine sample and were interviewed using measures of work-related stress. Their blood pressure was taken at a civil-service medical clinic and was self-measured at home. RESULTS: Systolic/diastolic pressure averaged ( +/- SD ) 135 +/- 19/84 +/- 14 mmHg at the clinic and 123 +/- 16/80 +/- 11 mmHG on self-measurements at home. The 24h urinary sodium excretion was 172 +/- 65 mmol. The overall stress score was categorized as low in 98 men, medium in 193 men and high in 93 men. Stress itself was not associated with an elevated pressure. However, in multivariate analyses with adjustments for age and body mass index, a stress-sodium interaction in the determination of the clinic systolic (P = 0.05) and diastolic (P = 0.08) pressure became apparent. At a sodium excretion of 100 mmol/24h (10th percentile), increasing stress from low to high was associated with a fall in pressure, averaging 4.5 mmHg for systolic pressure and 1.4 mmHg for diastolic pressure. By contrast, at 250 mmol/24h (90th percentile) the same stress increase was associated with a rise in pressure of 6.3 mmHg systolic and 5.9 mmHg diastolic. CONCLUSION: The present study suggests that sodium intake and work-related stress may interact to determine blood pressure. This interaction is probably dynamic in nature, so that the contribution of each factor to blood pressure can only be determined if both are measured.

Adult↗
PubMed1994

Hypertension caused by low-level lead exposure: myth or fact?

BACKGROUND: Several reports on the possible association between low-level lead exposure and blood pressure reflect diverging views. This meta-analysis aimed to find a common denominator in the published literature and to estimate whether a relationship exists between blood pressure and levels of lead in the blood. METHODS: Of the studies reviewed, 23 provided sufficient details to be considered. The meta-analysis included 33 groups with a total of 33 141 subjects, who had been recruited from the general population in 13 surveys and from occupational groups in 10 studies. In all but four studies the results were adjusted for age, and most studies took into account additional confounding factors. RESULTS: The association between blood pressure and blood lead was similar in both men and women. In the combined studies, a twofold increase in blood lead concentration was associated with a 1.0 mmHg rise in systolic pressure (confidence interval 0.4-1.6 mmHg; P = 0.002) and with a 0.6 mmHg increase in diastolic pressure (confidence interval 0.2-1.0 mmHg; P = 0.02). The association with systolic pressure strongly relied on the inclusion of a large study (n = 3851) in which women's blood pressure was measured at the end of pregnancy. The association with diastolic pressure was largely due to a population survey in the USA (n = 6289). There was no relationship across studies between the strength of the blood pressure-blood lead relationship and the mean blood lead concentration. CONCLUSION: The published evidence suggests that there can only be a weak positive association between blood pressure and lead exposure. Any such relationship may not be causal and is unlikely to entail any public-health implication in terms of hypertension-related complications. Nevertheless, these assumptions need to be confirmed in prospective population studies.

Blood Pressure↗
PubMed1994

Cough with angiotensin converting enzyme inhibitors: how much of a problem?

PURPOSE: To review the occurrence of angiotensin converting enzyme (ACE) inhibitor-related cough, and to examine its impact on the quality of life. DATA SOURCES: Data from published reports, postmarketing surveillance studies, hospital case series and randomly allocated controlled trials were reviewed. Data are presented from a nested case-control study examining the effects of ACE inhibitor-related cough in 36 subjects compared with 69 controls on various measures of quality of life. RESULTS: Low rates of ACE inhibitor-related cough were found in postmarketing studies, ranging from 0.1% (early studies) to 3%. Much higher figures were reported from double-blind randomly allocated controlled trials using self-administered questionnaires; the net increase over baseline was between 13 and 25% compared to 2% with the comparator drug. The nested case-control study suggested that the ACE inhibitor-related cough is associated with some deterioration in well-being. During ACE inhibitor treatment the patients tended to be more fatigued (P = 0.1) and depressed (P < 0.05) than controls. Reports of a sore throat increased by 27% (P < 0.01). CONCLUSIONS: Cough is a common side effect of ACE inhibitor treatment, with conservative estimates suggesting that around one in 10 patients treated with an ACE inhibitor will develop a dry persistent cough. Half of these may be withdrawn from treatment. This cough is probably associated with some deterioration in well-being, but larger studies are required to confirm this.

Angiotensin-Converting Enzyme Inhibitors↗
PubMed1994

Quality of life and the heart: evaluation of therapeutic alternatives.

The choice of criteria that should be used in cardiological disease in order to establish a meaningful measure of quality of life is influenced by the severity and nature of the disease, the expected benefits and adverse effects of treatment, and such considerations as the length of the study and availability of appropriate methods. Moreover, the selection of specific instrumentation should be made with a view to producing valid, repeatable results that allow sensitive assessment of the effects of treatment. The inclusion of a health index is one method of obtaining quality-of-life scores from patients who withdraw from a clinical trial or who die. Interpretation of quality-of-life results from clinical trials is not simple: for example, the effect of treatment must be distinguished from the benefit of trial inclusion; moreover, changes in quality-of-life scores should correspond to changes in the patients' own experiences of their daily lives. The measurement of quality of life, when the effect of treatment is being assessed, requires adequate control data. This usually necessitates a double-blind, randomised trial protocol. The quality of life of patients on long-term pharmacological treatment needs to be evaluated, and several groups of drugs commonly employed are discussed here. Transdermal nitrates for angina do impair quality of life if used continuously, by producing headaches and limiting social participation, while tolerance limits their efficacy.(ABSTRACT TRUNCATED AT 250 WORDS)

Angina Pectoris↗
PubMed1993

Smoking and blood pressure in the leg.

OBJECTIVES: To determine whether the calf:brachial ratio for systolic blood pressure is reduced in both current and ex-smokers of cigarettes. DESIGN: Cross-sectional study of the calf:brachial systolic blood pressure ratio and smoking history. SUBJECTS: Four hundred and ten male and 138 female civil servants aged 35-59 years working in the Department of the Environment Building, London. RESULTS: In men the systolic blood pressure ratio (Doppler calf:auscultatory brachial) decreased above the age of 50 years. However, different patterns were observed in those who had smoked at some time and those who had never smoked. In those who had never smoked the ratio in men aged 35-44 years was lower than that in men aged 55-59 years. In those who had smoked the average ratio rose from the age of 35-44 years to the age of 45-49 years and then fell to below the former value at the age of 55-59 years. There was a significant difference between lifelong non-smokers and current smokers at age 55-59 years. The pattern was similar in both male ex- and current smokers, and ex-smokers had results intermediate between those for current smokers and those who had never smoked. In women who had never smoked the ratio increased from the age of 35-44 years to the age of 50-59 years. In women aged 50-59 who currently smoke or used to smoke cigarettes the average ratio was close to that for women aged 35-44 years who had never smoked. CONCLUSIONS: The calf:brachial systolic blood pressure ratio is a simple measurement that may prove useful in detecting the early adverse effects of smoking on peripheral vascular disease. Lower ratios at older ages occurred in both current and ex-smokers, and the effects of smoking on peripheral arterial disease may not be easily reversible at older ages.

Adult↗
PubMed1993

The relationship between blood pressure and sodium and potassium excretion during the day and at night.

OBJECTIVE: The relationships between blood pressure and the urinary excretion rates of sodium and potassium during the day and at night were investigated. METHODS: A total of 160 participants (135 normotensive subjects and 25 untreated patients with essential hypertension) were examined using ambulatory blood pressure monitoring and timed urine collections during waking and sleeping hours. RESULTS: Blood pressure averaged 126/79 mmHg during waking hours and 107/62 mmHg during sleep. More sodium, potassium and aldosterone were excreted during the daytime, but the natriuretic substance kallikrein was excreted at a fixed rate throughout the 24 h. During waking hours there was poor correlation between blood pressure and urinary sodium and potassium excretion. By contrast, at night when the aldosterone: kallikrein ratio fell, the sodium and potassium excretion rates were positively correlated with blood pressure. CONCLUSIONS: Pressure natriuresis, not apparent during waking hours, may be unmasked at night when the balance between sodium-retaining and sodium-losing mechanisms favours natriuresis. Thus, the relationship between blood pressure and 24-h sodium excretion, usually considered to show the influence of salt intake on blood pressure, may also reflect pressure-induced natriuresis, if urine is more completely collected at night than during the day, and in circumstances favouring sodium retention during the day and sodium loss during sleep.

Adult↗